{"denoms":[{"counts":[{"groupId":"BG000","value":"208"},{"groupId":"BG001","value":"308"},{"groupId":"BG002","value":"516"}],"units":"Participants"}],"groups":[{"description":"Eligible participants were administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to 24 weeks and were followed up to Week 104.","id":"BG000","title":"Placebo Plus Methotrexate"},{"description":"Eligible Participants were administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and were followed up to Week 104.","id":"BG001","title":"Rituximab Plus Methotrexate"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"20","upperLimit":"79","value":"55.0"},{"groupId":"BG001","lowerLimit":"20","upperLimit":"81","value":"53.0"},{"groupId":"BG002","lowerLimit":"20","upperLimit":"81","value":"53.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"251"},{"groupId":"BG002","value":"419"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"97"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety population included participants who were randomized and received any part of an infusion of the study drug."}